Xpert Mycobacterium tuberculosis/rifampicin assay

A boon in tuberculosis diagnostics

Kavya Ramamurthy, Sevitha Bhat, Shalini Shenoy, Aseem Rangnekar

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objectives: Mycobacterium tuberculosis (MTB) remains one of the most significant causes of mortality and morbidity in developing countries especially India. India has the highest burden of TB, with an estimated incidence figure of 2.1 million cases out of the 9 million cases of TB globally. Diagnosis of TB relies on conventional microscopy and culture with drawbacks related to sensitivity, specificity, turn around time (TAT). The aim of this study was to evaluate the performance of Xpert MTB/rifampicin (RIF) assay (GX) for MTB detection in pulmonary and extrapulmonary clinical samples. Methods: A total of 209 clinical specimens (182: pulmonary and 27: extrapulmonary) were processed using auramine smear, culture by mycobacteria growth indicator tube and GenXpert. Results: The sensitivity of GenXpert was 62.63% for pulmonary and 55% for extrapulmonary samples. The sensitivity and specificity of GX were 100% for the smear positive cases. The sensitivity, specificity, positive predictive value, and negative predictive value of the GX for smear negative cases were 67.8%, 97.5%, 90.4%, and 89.6%, respectively. RIF resistance was detected in 3.8% the samples. Conclusion: GenXpert, with short TAT, high sensitivity, specificity and less technical expertise required is a promising tool in TB diagnostics for the future.

Original languageEnglish
Pages (from-to)225-227
Number of pages3
JournalAsian Journal of Pharmaceutical and Clinical Research
Volume9
Issue number5
Publication statusPublished - 01-09-2016

Fingerprint

Rifampin
Mycobacterium tuberculosis
Tuberculosis
Sensitivity and Specificity
Lung
India
Benzophenoneidum
Professional Competence
Mycobacterium
Developing Countries
Microscopy
Morbidity
Mortality
Incidence
Growth

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmaceutical Science
  • Pharmacology (medical)

Cite this

@article{60b100b53ba44c7bb0d9f6083b6b1f6f,
title = "Xpert Mycobacterium tuberculosis/rifampicin assay: A boon in tuberculosis diagnostics",
abstract = "Objectives: Mycobacterium tuberculosis (MTB) remains one of the most significant causes of mortality and morbidity in developing countries especially India. India has the highest burden of TB, with an estimated incidence figure of 2.1 million cases out of the 9 million cases of TB globally. Diagnosis of TB relies on conventional microscopy and culture with drawbacks related to sensitivity, specificity, turn around time (TAT). The aim of this study was to evaluate the performance of Xpert MTB/rifampicin (RIF) assay (GX) for MTB detection in pulmonary and extrapulmonary clinical samples. Methods: A total of 209 clinical specimens (182: pulmonary and 27: extrapulmonary) were processed using auramine smear, culture by mycobacteria growth indicator tube and GenXpert. Results: The sensitivity of GenXpert was 62.63{\%} for pulmonary and 55{\%} for extrapulmonary samples. The sensitivity and specificity of GX were 100{\%} for the smear positive cases. The sensitivity, specificity, positive predictive value, and negative predictive value of the GX for smear negative cases were 67.8{\%}, 97.5{\%}, 90.4{\%}, and 89.6{\%}, respectively. RIF resistance was detected in 3.8{\%} the samples. Conclusion: GenXpert, with short TAT, high sensitivity, specificity and less technical expertise required is a promising tool in TB diagnostics for the future.",
author = "Kavya Ramamurthy and Sevitha Bhat and Shalini Shenoy and Aseem Rangnekar",
year = "2016",
month = "9",
day = "1",
language = "English",
volume = "9",
pages = "225--227",
journal = "Asian Journal of Pharmaceutical and Clinical Research",
issn = "0974-2441",
publisher = "Innovare Academics Sciences Pvt. Ltd",
number = "5",

}

Xpert Mycobacterium tuberculosis/rifampicin assay : A boon in tuberculosis diagnostics. / Ramamurthy, Kavya; Bhat, Sevitha; Shenoy, Shalini; Rangnekar, Aseem.

In: Asian Journal of Pharmaceutical and Clinical Research, Vol. 9, No. 5, 01.09.2016, p. 225-227.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Xpert Mycobacterium tuberculosis/rifampicin assay

T2 - A boon in tuberculosis diagnostics

AU - Ramamurthy, Kavya

AU - Bhat, Sevitha

AU - Shenoy, Shalini

AU - Rangnekar, Aseem

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Objectives: Mycobacterium tuberculosis (MTB) remains one of the most significant causes of mortality and morbidity in developing countries especially India. India has the highest burden of TB, with an estimated incidence figure of 2.1 million cases out of the 9 million cases of TB globally. Diagnosis of TB relies on conventional microscopy and culture with drawbacks related to sensitivity, specificity, turn around time (TAT). The aim of this study was to evaluate the performance of Xpert MTB/rifampicin (RIF) assay (GX) for MTB detection in pulmonary and extrapulmonary clinical samples. Methods: A total of 209 clinical specimens (182: pulmonary and 27: extrapulmonary) were processed using auramine smear, culture by mycobacteria growth indicator tube and GenXpert. Results: The sensitivity of GenXpert was 62.63% for pulmonary and 55% for extrapulmonary samples. The sensitivity and specificity of GX were 100% for the smear positive cases. The sensitivity, specificity, positive predictive value, and negative predictive value of the GX for smear negative cases were 67.8%, 97.5%, 90.4%, and 89.6%, respectively. RIF resistance was detected in 3.8% the samples. Conclusion: GenXpert, with short TAT, high sensitivity, specificity and less technical expertise required is a promising tool in TB diagnostics for the future.

AB - Objectives: Mycobacterium tuberculosis (MTB) remains one of the most significant causes of mortality and morbidity in developing countries especially India. India has the highest burden of TB, with an estimated incidence figure of 2.1 million cases out of the 9 million cases of TB globally. Diagnosis of TB relies on conventional microscopy and culture with drawbacks related to sensitivity, specificity, turn around time (TAT). The aim of this study was to evaluate the performance of Xpert MTB/rifampicin (RIF) assay (GX) for MTB detection in pulmonary and extrapulmonary clinical samples. Methods: A total of 209 clinical specimens (182: pulmonary and 27: extrapulmonary) were processed using auramine smear, culture by mycobacteria growth indicator tube and GenXpert. Results: The sensitivity of GenXpert was 62.63% for pulmonary and 55% for extrapulmonary samples. The sensitivity and specificity of GX were 100% for the smear positive cases. The sensitivity, specificity, positive predictive value, and negative predictive value of the GX for smear negative cases were 67.8%, 97.5%, 90.4%, and 89.6%, respectively. RIF resistance was detected in 3.8% the samples. Conclusion: GenXpert, with short TAT, high sensitivity, specificity and less technical expertise required is a promising tool in TB diagnostics for the future.

UR - http://www.scopus.com/inward/record.url?scp=84988527774&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988527774&partnerID=8YFLogxK

M3 - Article

VL - 9

SP - 225

EP - 227

JO - Asian Journal of Pharmaceutical and Clinical Research

JF - Asian Journal of Pharmaceutical and Clinical Research

SN - 0974-2441

IS - 5

ER -